mupirocin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1857 12650-69-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mupirocin
  • mupricin
  • pseudomonic acid
  • turixin
  • mupirocin calcium
  • bactroban
  • BRL 4910A
A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.
  • Molecular weight: 500.63
  • Formula: C26H44O9
  • CLOGP: 1.54
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 4
  • TPSA: 146.05
  • ALOGS: -4.28
  • ROTB: 17

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1987 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 501.24 15.45 156 8165 14232 50582571
Hyperchlorhydria 38.56 15.45 13 8308 1515 50595288
Nasal vestibulitis 38.49 15.45 6 8315 16 50596787
Purpura senile 32.85 15.45 9 8312 520 50596283
Folate deficiency 31.77 15.45 12 8309 1943 50594860
Drug ineffective 31.09 15.45 235 8086 819098 49777705
Chronic sinusitis 29.22 15.45 16 8305 6129 50590674
Tarsal tunnel syndrome 28.11 15.45 8 8313 531 50596272
Staphylococcal infection 26.56 15.45 31 8290 35585 50561218
Therapy interrupted 24.90 15.45 23 8298 20129 50576674
Toxicity to various agents 24.64 15.45 3 8318 212496 50384307
Hospitalisation 23.54 15.45 41 8280 67896 50528907
Resorption bone increased 23.16 15.45 8 8313 1003 50595800
Odynophagia 23.03 15.45 14 8307 6518 50590285
Vestibular disorder 21.38 15.45 8 8313 1261 50595542
Product dose omission issue 20.82 15.45 72 8249 183766 50413037
Cellulitis 19.84 15.45 39 8282 70759 50526044
Bronchial oedema 18.03 15.45 4 8317 95 50596708
Vertigo positional 16.13 15.45 8 8313 2503 50594300

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nasal vestibulitis 52.51 17.47 8 4546 19 29569954
Food aversion 42.36 17.47 10 4544 338 29569635
Staphylococcal infection 33.39 17.47 31 4523 29209 29540764
Pain of skin 27.86 17.47 13 4541 3802 29566171
Burkholderia test positive 27.79 17.47 9 4545 990 29568983
Dermatitis atopic 27.54 17.47 11 4543 2208 29567765
Skin discolouration 22.93 17.47 19 4535 15390 29554583
Cheilitis 21.37 17.47 9 4545 2067 29567906
Product dose omission issue 18.75 17.47 44 4510 96339 29473634
Toxic epidermal necrolysis 18.35 17.47 18 4536 18135 29551838
Exercise tolerance decreased 17.97 17.47 10 4544 4221 29565752

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Food aversion 34.86 14.59 10 10520 688 64487514
Hyperchlorhydria 32.82 14.59 12 10518 1787 64486415
Toxicity to various agents 31.66 14.59 10 10520 363503 64124699
Tarsal tunnel syndrome 28.69 14.59 8 10522 497 64487705
Purpura senile 28.59 14.59 8 10522 503 64487699
Product dose omission issue 27.60 14.59 82 10448 194665 64293537
Cellulitis 27.00 14.59 52 10478 93605 64394597
Resorption bone increased 25.88 14.59 9 10521 1159 64487043
Pain of skin 25.19 14.59 17 10513 9530 64478672
Folate deficiency 24.59 14.59 11 10519 2752 64485450
Pneumonia 21.25 14.59 160 10370 559416 63928786
Skin discolouration 20.51 14.59 27 10503 35228 64452974
Odynophagia 20.40 14.59 15 10515 9626 64478576
Therapy interrupted 19.50 14.59 20 10510 20016 64468186
Chronic sinusitis 18.53 14.59 12 10518 6280 64481922
Skin infection 18.36 14.59 17 10513 15020 64473182
Steroid withdrawal syndrome 18.32 14.59 6 10524 644 64487558
Bronchial oedema 18.27 14.59 4 10526 90 64488112
Staphylococcal infection 18.25 14.59 31 10499 50647 64437555
Dermatitis atopic 18.24 14.59 10 10520 3866 64484336
Macular degeneration 17.09 14.59 11 10519 5699 64482503
Surgery 17.02 14.59 22 10508 28191 64460011
Skin exfoliation 16.88 14.59 28 10502 44857 64443345
Vestibular disorder 16.87 14.59 8 10522 2285 64485917
Knee operation 16.73 14.59 10 10520 4547 64483655
Weight decreased 16.55 14.59 91 10439 285648 64202554
Procedural pain 16.04 14.59 16 10514 15492 64472710
Skin cancer 15.52 14.59 14 10516 11960 64476242
Psoriasis 15.07 14.59 35 10495 71668 64416534
Vertigo positional 15.07 14.59 8 10522 2903 64485299
Otitis externa fungal 14.85 14.59 3 10527 45 64488157
Dermatitis contact 14.68 14.59 12 10518 8988 64479214
Tissue injury 14.67 14.59 3 10527 48 64488154

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D06AX09 DERMATOLOGICALS
ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
ANTIBIOTICS FOR TOPICAL USE
Other antibiotics for topical use
ATC R01AX06 RESPIRATORY SYSTEM
NASAL PREPARATIONS
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
Other nasal preparations
FDA EPC N0000175515 RNA Synthetase Inhibitor Antibacterial
FDA MoA N0000175516 RNA Synthetase Inhibitors
CHEBI has role CHEBI:36047 antibacterial drugs
CHEBI has role CHEBI:48001 protein synthesis inhibitors
CHEBI has role CHEBI:35441 antiinfective agents
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011500 Protein Synthesis Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Impetigo indication 48277006 DOID:8504
Staph Aureus Traumatic Skin Lesion Infection indication
Methicillin-Resistant Staphylococcus Aureus Nasal Colonization indication
Traumatic Skin Lesion Streptococcus Pyogenes Infection indication
Folliculitis off-label use 13600006 DOID:4409
Atopic dermatitis off-label use 24079001 DOID:3310
Eczema off-label use 43116000
Epidermolysis bullosa off-label use 61003004 DOID:2730
Ecthyma off-label use 85791004
Furunculosis off-label use 112650006
Minor Bacterial Skin Infections off-label use
Skin irritation contraindication 367466007




🐶 Veterinary Drug Use

SpeciesUseRelation
Dogs Bacterial infections of the skin caused by strains of Staphylococcus aureus Indication
Dogs Bacterial infections of the skin caused by Staphylococcus intermedius Indication

🐶 Veterinary products

ProductApplicantIngredients
Bactoderm Ointment Zoetis Inc. 1
Muricin Fougera Pharmaceuticals Inc. 1
Mupirocin Ointment USP, 2% Taro Pharmaceuticals U.S.A. Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.76 acidic
pKa2 12.42 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 2% BASE MUPIROCIN ALEOR DERMACEUTICALS A213053 Nov. 16, 2021 RX CREAM TOPICAL June 27, 2022 COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Isoleucine--tRNA ligase, cytoplasmic Enzyme IC50 9.10 CHEMBL
Isoleucine--tRNA ligase Enzyme INHIBITOR DRUGBANK CHEMBL
Isoleucine--tRNA ligase Enzyme INHIBITOR CHEMBL CHEMBL
Isoleucine--tRNA ligase Enzyme Ki 8.60 CHEMBL
Isoleucine--tRNA ligase Enzyme Ki 7.22 CHEMBL
Isoleucine--tRNA ligase, putative, EC 6.1.1.5 Unclassified IC50 7.24 IUPHAR

External reference:

IDSource
4019345 VUID
N0000147519 NUI
D01076 KEGG_DRUG
115074-43-6 SECONDARY_CAS_RN
4019345 VANDF
4021018 VANDF
C0085259 UMLSCUI
CHEBI:7025 CHEBI
MRC PDB_CHEM_ID
CHEMBL3989715 ChEMBL_ID
CHEMBL2068726 ChEMBL_ID
CHEMBL719 ChEMBL_ID
D016712 MESH_DESCRIPTOR_UI
DB00410 DRUGBANK_ID
10916 IUPHAR_LIGAND_ID
5276 INN_ID
D0GX863OA5 UNII
446596 PUBCHEM_CID
221128 RXNORM
198973 MMSL
47751 MMSL
5138 MMSL
5139 MMSL
720 MMSL
002802 NDDF
005869 NDDF
387397004 SNOMEDCT_US
441528009 SNOMEDCT_US
71453003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1010 OINTMENT 20 mg TOPICAL ANDA 23 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 0168-0352 OINTMENT 20 mg TOPICAL ANDA 23 sections
BACTROBAN HUMAN PRESCRIPTION DRUG LABEL 1 16590-028 CREAM 20 mg TOPICAL NDA 22 sections
MUPIROCIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-158 OINTMENT 20 mg TOPICAL ANDA 16 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 16714-055 CREAM 20 mg TOPICAL ANDA 28 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 17856-0112 OINTMENT 20 mg TOPICAL ANDA 20 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 21695-188 OINTMENT 20 mg TOPICAL ANDA 19 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 21922-029 CREAM 2 g TOPICAL ANDA 23 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 42254-137 OINTMENT 20 mg TOPICAL ANDA 19 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 42254-229 OINTMENT 20 mg TOPICAL ANDA 20 sections
CENTANY HUMAN PRESCRIPTION DRUG LABEL 1 43538-300 OINTMENT 20 mg TOPICAL NDA 26 sections
Centany AT HUMAN PRESCRIPTION DRUG LABEL 1 43538-310 OINTMENT 20 mg TOPICAL NDA 26 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 45802-112 OINTMENT 20 mg TOPICAL ANDA 24 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 45865-722 OINTMENT 20 mg TOPICAL ANDA 20 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 49999-644 OINTMENT 20 mg TOPICAL ANDA 20 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50090-1587 OINTMENT 20 mg TOPICAL ANDA 24 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50090-4349 OINTMENT 20 mg TOPICAL ANDA 24 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50090-4397 OINTMENT 20 mg TOPICAL ANDA 24 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50268-568 OINTMENT 20 mg TOPICAL ANDA 25 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50436-0025 OINTMENT 20 mg TOPICAL ANDA 23 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50436-0112 OINTMENT 20 mg TOPICAL ANDA 24 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50436-0180 OINTMENT 20 mg TOPICAL ANDA 22 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50436-1010 OINTMENT 20 mg TOPICAL ANDA 23 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 51672-1312 OINTMENT 20 mg TOPICAL ANDA 25 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 51672-1370 CREAM 20 mg TOPICAL ANDA 28 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 52959-743 OINTMENT 20 mg TOPICAL ANDA 20 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 53002-9850 OINTMENT 20 mg TOPICAL ANDA 22 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 53002-9851 OINTMENT 20 mg TOPICAL ANDA 24 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 53002-9852 OINTMENT 20 mg TOPICAL ANDA 23 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 53002-9853 OINTMENT 20 mg TOPICAL ANDA 24 sections